2023-503683-16-00CompletedPhase 1
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Breye Therapeutics ApS
- Enrollment
- 3
- Locations
- 4
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Ulrik Mouritzen
Scientific
Breye Therapeutics ApS
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.2023-504949-31-00AstraZeneca AB37
Recruiting
Phase 1
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers2024-518889-27-00SmartDyeLivery GmbH48
Completed
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease2023-504412-14-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG20
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
Recruiting
Phase 1
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22